These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Cho JY Curr Gene Ther; 2002 Dec; 2(4):393-402. PubMed ID: 12477251 [TBL] [Abstract][Full Text] [Related]
25. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726 [TBL] [Abstract][Full Text] [Related]
28. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420 [TBL] [Abstract][Full Text] [Related]
29. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Müller AM; Schmohl KA; Knoop K; Schug C; Urnauer S; Hagenhoff A; Clevert DA; Ingrisch M; Niess H; Carlsen J; Zach C; Wagner E; Bartenstein P; Nelson PJ; Spitzweg C Oncotarget; 2016 Aug; 7(34):54795-54810. PubMed ID: 27458162 [TBL] [Abstract][Full Text] [Related]
30. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC Gene Ther; 2010 Nov; 17(11):1325-32. PubMed ID: 20428214 [TBL] [Abstract][Full Text] [Related]
31. Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice. Kitzberger C; Spellerberg R; Han Y; Schmohl KA; Stauss C; Zach C; Kälin RE; Multhoff G; Eiber M; Schilling F; Glass R; Weber WA; Wagner E; Nelson PJ; Spitzweg C Clin Cancer Res; 2023 Mar; 29(5):930-942. PubMed ID: 36516189 [TBL] [Abstract][Full Text] [Related]
32. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050 [TBL] [Abstract][Full Text] [Related]
33. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. Carlson SK; Classic KL; Hadac EM; Dingli D; Bender CE; Kemp BJ; Russell SJ AJR Am J Roentgenol; 2009 Jan; 192(1):279-87. PubMed ID: 19098211 [TBL] [Abstract][Full Text] [Related]
34. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter ( Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510 [No Abstract] [Full Text] [Related]
35. Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Huang R; Zhao Z; Ma X; Li S; Gong R; Kuang A Cancer Gene Ther; 2011 Feb; 18(2):144-52. PubMed ID: 21037556 [TBL] [Abstract][Full Text] [Related]
36. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach. Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253 [TBL] [Abstract][Full Text] [Related]